Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML
Year: 2018
Type: article
Source: Leukemia
Authors: Dyana T. Saenz, Warren Fiskus, Taghi Manshouri, Christopher P. Mill, Yimin Qian, Kanak Raina, Kimal Rajapakshe, Cristian Coarfa, Raffaella Soldi, Prithviraj Bose, Gautam Borthakur, Tapan M. Kadia, Joseph D. Khoury, Lucia Masarova, Agnieszka J. Nowak, Baohua Sun, David N. Saenz, Steven M. Kornblau, Steve Horrigan, Sunil Sharma, Peng Qiu, Craig M. Crews, Srdan Verstovsek, Kapil N. Bhalla
Institutions: The University of Texas MD Anderson Cancer Center, Arvinas (United States), Baylor College of Medicine, BetaCat Pharmaceuticals (United States), Translational Genomics Research Institute, Georgia Institute of Technology, Emory University, The Wallace H. Coulter Department of Biomedical Engineering, Yale University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: SPORE University of Texas M. D. Anderson Cancer Center-Leukemia, Targeted Therapy for AML Stem Cells, G7500302123, G7758079373, Inducing Proximity: An Emerging Paradigm for New Therapeutic Modalities, Cancer Center Support Grant, Baylor College of Medicine Cancer Center - Cancer Center Support Grant
OpenAlex ID: W2906093598